SVB Securities analyst Roanna Ruiz maintained a Buy rating on Vir Biotechnology (VIR – Research Report) today and set a price target of $43.00. The company’s shares closed yesterday at $29.99.
According to TipRanks, Ruiz is an analyst with an average return of -35.0% and a 22.03% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Lantheus, Enanta Pharmaceuticals, and scPharmaceuticals.
Vir Biotechnology has an analyst consensus of Strong Buy, with a price target consensus of $57.50, implying a 91.73% upside from current levels. In a report released on January 25, Needham also reiterated a Buy rating on the stock with a $32.00 price target.
See the top stocks recommended by analysts >>
VIR market cap is currently $4.11B and has a P/E ratio of 3.53.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
Read More on VIR:
- Vir Biotechnology announces retirement of CEO, Backer to succeed
- Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
- Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
- Vir Biotechnology achieves target enrollment for Phase 2 PENINSULA trial